Healis Therapeutics is focused on developing innovative neuromuscular treatments for psychiatric conditions, particularly major depressive disorder (MDD). The company is pioneering the use of botulinum toxin-based therapies, leveraging its unique properties to modulate emotional responses and potentially alleviate symptoms of depression. Their research includes a partnership with Massachusetts General Hospital and Harvard Medical School to advance clinical-stage neuroscience research, as well as a supply agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications. Healis has also acquired key intellectual property related to MDD, which is expected to accelerate the development of their therapeutic candidates.

The scientific foundation of Healis Therapeutics' approach is supported by a growing body of clinical research demonstrating the efficacy of botulinum toxin A in treating depression. Various studies have shown that botulinum toxin can positively influence mood and cognitive function, with mechanisms involving modulation of brain activity related to emotional processing. The company is actively engaged in clinical trials and has presented findings that highlight the antidepressant effects of botulinum toxin, suggesting a new paradigm in psychiatric treatment. Their commitment to advancing neurotherapeutics is evident in their participation in industry events and collaborations aimed at enhancing the understanding and application of these novel treatments.

United States

Healis Therapeutics is a neurotherapeutics company advancing the treatment of neuropsychiatric and neurodegenerative disease.

Healis Therapeutics

Company Details